Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CATXNASDAQ:HYPRNASDAQ:STIMNASDAQ:TCMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCATXPerspective Therapeutics$3.17-1.6%$2.47$1.60▼$16.55$235.30M1.091.09 million shs815,918 shsHYPRHyperfine$0.72-2.4%$0.70$0.53▼$1.90$56.20M0.95897,316 shs463,364 shsSTIMNeuronetics$3.79-0.5%$4.07$0.52▼$5.92$249.46M1.92769,884 shs297,721 shsTCMDTactile Systems Technology$9.84-1.1%$11.52$8.61▼$21.10$228.76M0.94262,227 shs271,092 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCATXPerspective Therapeutics0.00%-4.52%+31.54%+22.39%-76.17%HYPRHyperfine0.00%-9.32%+20.37%-21.44%-17.01%STIMNeuronetics0.00%+1.88%-11.86%-16.15%+87.62%TCMDTactile Systems Technology0.00%-1.99%+1.97%-25.23%-17.93%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCATXPerspective Therapeutics2.8289 of 5 stars3.63.00.00.03.32.50.0HYPRHyperfine3.3608 of 5 stars3.33.00.00.03.52.51.3STIMNeuronetics1.9598 of 5 stars3.32.00.00.01.61.70.6TCMDTactile Systems Technology3.7845 of 5 stars3.02.00.00.03.82.53.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCATXPerspective Therapeutics 3.20Buy$12.63298.26% UpsideHYPRHyperfine 2.67Moderate Buy$1.0646.81% UpsideSTIMNeuronetics 2.67Moderate Buy$5.5045.12% UpsideTCMDTactile Systems Technology 2.00Hold$16.0062.60% UpsideCurrent Analyst Ratings BreakdownLatest HYPR, STIM, CATX, and TCMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2025HYPRHyperfineB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy6/3/2025CATXPerspective TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$15.00 ➝ $16.005/15/2025HYPRHyperfineB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$1.20 ➝ $1.005/14/2025CATXPerspective TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $8.005/14/2025HYPRHyperfineWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$1.29 ➝ $0.685/13/2025CATXPerspective TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$11.005/7/2025TCMDTactile Systems TechnologyB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold5/6/2025TCMDTactile Systems TechnologyPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral$25.00 ➝ $14.004/7/2025CATXPerspective TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$21.00 ➝ $10.003/31/2025CATXPerspective TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/27/2025CATXPerspective TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$16.00 ➝ $15.00(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCATXPerspective Therapeutics$1.43M164.55N/AN/A$2.67 per share1.19HYPRHyperfine$11.73M4.79N/AN/A$1.17 per share0.62STIMNeuronetics$89.45M2.79N/AN/A$1.18 per share3.21TCMDTactile Systems Technology$293.16M0.78$0.69 per share14.21$9.18 per share1.07Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCATXPerspective Therapeutics-$46.51MN/A0.00N/AN/A-4,096.66%-27.40%-23.16%8/11/2025 (Estimated)HYPRHyperfine-$44.24M-$0.54N/AN/AN/A-309.42%-57.54%-50.38%8/6/2025 (Estimated)STIMNeuronetics-$30.19M-$1.31N/AN/AN/A-50.09%-141.24%-32.77%8/11/2025 (Estimated)TCMDTactile Systems Technology$28.51M$0.6614.0611.71N/A5.79%9.37%6.75%8/4/2025 (Estimated)Latest HYPR, STIM, CATX, and TCMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025HYPRHyperfine-$0.12-$0.12N/A-$0.12$2.82 million$2.14 million5/6/2025Q1 2025STIMNeuronetics-$0.13-$0.21-$0.08-$0.21$29.07 million$31.98 million5/5/2025Q1 2025TCMDTactile Systems Technology-$0.07-$0.13-$0.06-$0.13$63.48 million$61.27 million3/17/2025Q4 2024HYPRHyperfine-$0.16-$0.14+$0.02-$0.14$2.30 million$2.32 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCATXPerspective TherapeuticsN/AN/AN/AN/AN/AHYPRHyperfineN/AN/AN/AN/AN/ASTIMNeuroneticsN/AN/AN/AN/AN/ATCMDTactile Systems TechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCATXPerspective TherapeuticsN/A9.609.60HYPRHyperfineN/A6.445.73STIMNeuronetics4.903.162.87TCMDTactile Systems Technology0.114.363.80Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCATXPerspective Therapeutics54.66%HYPRHyperfine15.03%STIMNeuronetics53.59%TCMDTactile Systems Technology83.43%Insider OwnershipCompanyInsider OwnershipCATXPerspective Therapeutics3.72%HYPRHyperfine30.98%STIMNeuronetics8.70%TCMDTactile Systems Technology2.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCATXPerspective Therapeutics7074.23 million65.21 millionOptionableHYPRHyperfine19077.83 million51.49 millionOptionableSTIMNeuronetics18065.82 million27.37 millionOptionableTCMDTactile Systems Technology98023.25 million23.36 millionOptionableHYPR, STIM, CATX, and TCMD HeadlinesRecent News About These CompaniesTwo Sigma Investments LP Sells 31,793 Shares of Tactile Systems Technology, Inc. (NASDAQ:TCMD)June 9, 2025 | marketbeat.comBank of America Corp DE Raises Stake in Tactile Systems Technology, Inc. (NASDAQ:TCMD)June 4, 2025 | marketbeat.comNew Data Demonstrates Significant Clinical and Quality-of-Life Benefits of Flexitouch® Plus in Treating Lymphedema Among Head and Neck Cancer SurvivorsJune 3, 2025 | globenewswire.comMillennium Management LLC Buys New Shares in Tactile Systems Technology, Inc. (NASDAQ:TCMD)June 1, 2025 | marketbeat.comTactile Systems Technology, Inc. (NASDAQ:TCMD) Shares Sold by Nuveen Asset Management LLCMay 29, 2025 | marketbeat.comBNP Paribas Financial Markets Sells 26,955 Shares of Tactile Systems Technology, Inc. (NASDAQ:TCMD)May 29, 2025 | marketbeat.comTactile Systems Technology, Inc. (NASDAQ:TCMD) Shares Bought by Tidal Investments LLCMay 27, 2025 | marketbeat.comMan Group plc Invests $579,000 in Tactile Systems Technology, Inc. (NASDAQ:TCMD)May 27, 2025 | marketbeat.comTactile Systems Technology, Inc. (NASDAQ:TCMD) Stock Position Lessened by D. E. Shaw & Co. Inc.May 26, 2025 | marketbeat.comAmeriprise Financial Inc. Sells 37,472 Shares of Tactile Systems Technology, Inc. (NASDAQ:TCMD)May 26, 2025 | marketbeat.comJane Street Group LLC Purchases 34,846 Shares of Tactile Systems Technology, Inc. (NASDAQ:TCMD)May 25, 2025 | marketbeat.comTactile Medical to Present at Upcoming Investor Conferences in JuneMay 20, 2025 | globenewswire.comDeutsche Bank AG Decreases Stake in Tactile Systems Technology, Inc. (NASDAQ:TCMD)May 19, 2025 | marketbeat.comTactile Systems Technology, Inc. (NASDAQ:TCMD) CFO Sells $29,034.74 in StockMay 15, 2025 | insidertrades.comTactile Systems Technology's (NASDAQ:TCMD) Soft Earnings Don't Show The Whole PictureMay 13, 2025 | finance.yahoo.comTactile Systems Technology, Inc. (NASDAQ:TCMD) Director Sells $31,911.00 in StockMay 10, 2025 | insidertrades.comPiper Sandler Downgrades Tactile Systems Technology (TCMD)May 8, 2025 | msn.comAnalysts Have Been Trimming Their Tactile Systems Technology, Inc. (NASDAQ:TCMD) Price Target After Its Latest ReportMay 7, 2025 | finance.yahoo.comWhy Tactile Systems Technology, Inc.’s (TCMD) Stock Is Down 33.21%May 6, 2025 | aaii.comTactile Systems stock tumbles after Q1 missMay 6, 2025 | investing.comTactile Systems downgraded to Neutral from Overweight at Piper SandlerMay 6, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeWorkday Stock Price Implosion: An Automatic Buy for AI InvestorsBy Thomas Hughes | May 26, 2025View Workday Stock Price Implosion: An Automatic Buy for AI InvestorsGitLab: Buy It Low While You Still Can—Higher Prices Are ComingBy Thomas Hughes | June 11, 2025View GitLab: Buy It Low While You Still Can—Higher Prices Are ComingMid-Cap Marvels: 3 Stocks That Crushed Sales Estimates in MayBy Leo Miller | June 12, 2025View Mid-Cap Marvels: 3 Stocks That Crushed Sales Estimates in MayBroadcom Slides on Solid Earnings, AI Outlook Still StrongBy Leo Miller | June 6, 2025View Broadcom Slides on Solid Earnings, AI Outlook Still StrongHYPR, STIM, CATX, and TCMD Company DescriptionsPerspective Therapeutics NYSE:CATX$3.17 -0.05 (-1.55%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$3.26 +0.10 (+3.00%) As of 06/13/2025 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.Hyperfine NASDAQ:HYPR$0.72 -0.02 (-2.43%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$0.72 0.00 (-0.14%) As of 06/13/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Hyperfine, Inc., a medical device company, provides magnetic resonance imaging (MRI) products in the United States. The company offers Swoop Portable MR imaging system, which offers portable brain neuroimaging; and support and technical assistance services. It serves ICU, comprehensive, and primary stroke accredited facilities through direct sales and distributors. Hyperfine, Inc. was founded in 2014 and is based in Guilford, Connecticut.Neuronetics NASDAQ:STIM$3.79 -0.02 (-0.52%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$3.83 +0.04 (+0.95%) As of 06/13/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.Tactile Systems Technology NASDAQ:TCMD$9.84 -0.11 (-1.11%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$9.86 +0.02 (+0.15%) As of 06/13/2025 05:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tactile Systems Technology, Inc., a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema in the home setting; and Entre Plus System, a portable pneumatic compression device for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers. The company also provides Kylee, a mobile application to help patients learn about lymphedema, track their symptoms, and treatment, as well as to share their progress with their doctor; and AffloVest, a portable high frequency chest wall oscillation vest to treat patients with retained pulmonary secretions resulting from bronchiectasis, cystic fibrosis, and various neuromuscular disorders. Tactile Systems Technology, Inc. was incorporated in 1995 and is headquartered in Minneapolis, Minnesota. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
